Tildacerfont
Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia[1].
Product Specifications
CAS Number
1014983-00-6
Product Name Alternative
SPR001; LY2371712
UNSPSC
12352005
Target
CRFR
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tildacerfont.html
Purity
98.60
Solubility
DMSO : 10 mg/mL (ultrasonic)
Smiles
CCC(CC)C1=CC(C)=NC2=C(C(C)=NN12)C3=C(N=C(S3)N4CCOCC4)Cl
Molecular Formula
C20H26ClN5OS
Molecular Weight
419.97
References & Citations
[1]Prete A, et al. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021;186 (1) :R1-R14. Published 2021 Nov 30.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CRFR1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940994-100 1x 100 µL
TNF alpha (J2D10), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940149-100 1x 100 µL
CD106 / VCAM1 (1.4C3), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details